Phase 1 study of azacitidine in combination with evorpacept for higher-risk myelodysplastic syndrome (MDS)

被引：0
|
作者：
Garcia-Manero, Guillermo
Scott, Bart L.
Kishtagari, Ashwin
Sanikommu, Srinivasa R.
Al-Kali, Aref
Lee, Je-Hwan
Burgues, Juan M. Bergua
Diez-Campelo, Maria
Erba, Harry P.
Garcia-Hernandez, Carmen
Santillana, Guillermo Sanz
O'Connell, Casey
Jang, Jun-Ho
Shin, Dong-Yeop
Sayar, Hamid
Rao, Mayank
Schwartz, Richard S.
An, Grace
Jin, Feng
Forgie, Alison J.
Tsiatis, Athanasios C.
Altman, Jessica K.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT060
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT060
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS)
    Chen, James
    Johnson, Lisa
    McKenna, Kelly
    Choi, Timothy
    Duan, Jiaqi
    Feng, Dongdong
    Tsai, Jonathan
    Garcia-Martin, Natalia
    Sompalli, Kavitha
    Maute, Roy
    Vyas, Paresh
    Majeti, Ravindra
    Takimoto, Chris
    Liu, Jie
    Ramsingh, Giridharan
    Chao, Mark
    Volkmer, Jens-Peter
    Weissman, Irving
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S317 - S318
  • [22] Magrolimab plus Azacitidine Versus Azacitidine plus Placebo in Untreated Higher-Risk (HR) Myelodysplastic Syndromes (MDS): The Phase 3, Randomized, ENHANCE Study
    Garcia-Manero, Guillermo
    Daver, Naval
    Xu, Jin
    Chao, Mark
    Chung, Trisha
    Tan, Anderson
    Wang, Yan
    Wei, Andrew
    Vyas, Paresh
    Sallman, David
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S343 - S344
  • [23] Therapy of Myelodysplastic Syndrome (MDS) with azacitidine given in combination with etanercept: A phase II study
    Holsinger, Aaron L.
    Ramakrishnan, Aravind
    Storer, Barry
    Becker, Pamela S.
    Petersdorf, Stephen
    Deeig, H. Joachim
    Scott, Bart L.
    BLOOD, 2007, 110 (11) : 435A - 435A
  • [24] Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results.
    Sallman, David Andrew
    Al Malki, Monzr M.
    Asch, Adam Steven
    Wang, Eunice S.
    Jurcic, Joseph G.
    Bradley, Terrence J.
    Flinn, Ian W.
    Pollyea, Daniel Aaron
    Kambhampati, Suman
    Tanaka, Tiffany N.
    Zeidner, Joshua F.
    Garcia-Manero, Guillermo
    Jeyakumar, Deepa
    Gu, Lin
    Tan, Anderson
    Chao, Mark
    O'Hear, Carol Elaine
    Lal, Indu
    Vyas, Paresh
    Daver, Naval Guastad
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naive higher-risk myelodysplastic syndromes.
    Fong, Chun Yew
    Wei, Andrew H.
    Frattini, Mark G.
    Jacoby, Meagan
    Borate, Uma
    Gotze, Katharina S.
    Garcia, Jacqueline Suen
    Pollyea, Daniel Aaron
    Holes, Leanne
    Zhou, Ying
    Fakouhi, Kaffa Mussumeh
    Leverson, Joel
    Harb, Jason G.
    Agarwal, Suresh K.
    Attarchi, Faraneh
    Mabry, Mack H.
    Hong, Wan-Jen
    Jahn, Thomas Michael
    Fenaux, Pierre
    Garcia-Manero, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination With Azacitidine for the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 14 - 16
  • [27] Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study
    Garcia, Jacqueline S.
    Wei, Andrew H.
    Borate, Uma
    Fong, Chun Yew
    Baer, Maria R.
    Nolte, Florian
    Jurcic, Joseph G.
    Jacoby, Meagan A.
    Hong, Wan-Jen
    Platzbecker, Uwe
    Odenike, Olatoyosi
    Cunningham, Ilona
    Zhou, Ying
    Tong, Bo
    Hogdal, Leah
    Kamalakar, Rajesh
    Hutti, Jessica E.
    Kye, Steve
    Garcia-Manero, Guillermo
    BLOOD, 2020, 136
  • [28] Effectiveness of Azacitidine in Frontline Higher-Risk Myelodysplastic Syndrome: A Retrospective Cohort Study of 382 Patients
    Nishathan, Rajakumaraswamy
    Mitul, Gandhi
    Andrew, H. Wei
    David, A. Sallman
    Navel, G. Daver
    Shuyuan, Mo
    Shahed, Iqbal
    Manli, Chen
    Yunfei, Wang
    Paresh, Vyas
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S15 - S15
  • [29] Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome
    Chien, Kelly S.
    Borthakur, Gautam M.
    Naqvi, Kiran
    Daver, Naval G.
    Cortes, Jorge E.
    DiNardo, Courtney D.
    Jabbour, Elias
    Andreeff, Michael
    Alvarado, Yesid
    Bose, Prithviraj
    Jain, Nitin
    Sheppard, Kimberly
    Klingner-Winton, Cheri
    Pierce, Sherry A.
    Dong, Xiao Qin
    Soltysiak, Kelly
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2019, 134
  • [30] Phase 2, Randomized, Double-Blind Study of Pracinostat in Combination With Azacitidine in Patients With Untreated, Higher-Risk Myelodysplastic Syndromes
    Garcia-Manero, Guillermo
    Montalban-Bravo, Guillermo
    Berdeja, Jesus G.
    Abaza, Yasmin
    Jabbour, Elias
    Essell, James
    Lyons, Roger M.
    Ravandi, Farhad
    Maris, Michael
    Heller, Brian
    DeZern, Amy E.
    Babu, Sunil
    Wright, David
    Anz, Bertrand
    Boccia, Ralph
    Komrokji, Rami S.
    Kuriakose, Philip
    Reeves, James
    Sekeres, Mikkael A.
    Kantarjian, Hagop M.
    Ghalie, Richard
    Roboz, Gail J.
    CANCER, 2017, 123 (06) : 994 - 1002
12345